1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Eli Lilly and Company

Eli Lilly and Company

LLY
Eli Lilly and CompanyUS flagNew York Stock Exchange
1,083.23
USD
+19.08
- -
1.02TMarket Cap
Eli Lilly and Company
LLY
(New York Stock Exchange)

Recent

price

1,083.23

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
20.87
21.8
19.72
20.7
17.66
18.06
19.28
18.99
20.91
23.31
25.65
29.69
30.04
37.94
50.19
72.84
80.68
Revenue per Share
4.58
3.9
3.57
4.19
2.15
2.18
2.49
-0.19
3.14
8.69
6.47
5.85
6.57
5.83
11.8
23.07
28.23
Basic EPS, GAAP
5.13
4.97
3.72
4.16
2.6
1.21
3.41
3.28
2.44
3.64
4.67
5.65
4.84
-3.5
0.46
6.67
11.58
Free Cash Flow per Basic Share
1.96
1.96
1.91
1.9
1.89
1.92
1.96
2.08
2.25
2.52
2.81
3.24
3.72
4.52
5.21
6.02
6.24
Dividend per Share
11.51
14.02
14.66
15.84
15.47
15.11
15.2
13.86
11.73
5.76
8.81
10.02
11.19
12.13
15.75
28.01
33.62
Book Value per Share
6.87
7.55
8.74
11.92
9.68
4.99
5.22
3.11
8.25
-7.94
-5.64
-2.55
-0.53
-1.09
2.6
15.77
19.76
Tangible Book Value per Share
1,106
1,114
1,146
1,117
1,111
1,105
1,101
1,052
1,028
958
957
954
950
899
898
895
896
Basic Weighted Avg Shares
23,076
24,286
22,603
23,113
19,616
19,959
21,222
19,974
21,493
22,320
24,540
28,318
28,541
34,124
45,043
65,179
72,250
Sales/Revenue/Turnover
29.35
26.01
22.19
24
16.97
18
17.31
20.03
26.92
25.94
28.36
26.99
29.01
30.26
37.83
45.56
47.3
Operating Margin (%)
1,328
1,374
1,462
1,446
1,379
1,428
1,497
1,567
1,609
1,233
1,324
1,548
1,522
1,527
1,767
1,997
2,043
Depreciation Expense
5,070
4,348
4,089
4,685
2,390
2,408
2,738
-204
3,232
8,318
6,194
5,582
6,245
5,240
10,590
20,640
25,277
Net Income, GAAP
22.31
18.73
24.4
20.45
20.32
13.68
18.86
103.75
14.39
11.93
14.33
9.32
8.25
20.05
16.48
19.79
18.79
Effective Tax Rate (%)
21.97
17.9
18.09
20.27
12.19
12.07
12.9
-1.02
15.04
37.27
25.24
19.71
21.88
15.36
23.51
31.67
34.99
Profit Margin (%)
7,739
5,317
4,649
4,188
2,187
4,344
4,115
4,666
8,662
1,934
4,980
3,400
896
-1,566
4,364
20,401
18,201
Working Capital
6,770
5,465
5,519
4,200
5,333
7,972
8,368
9,940
9,196
13,818
16,587
15,346
14,738
18,321
28,527
40,868
39,370
LT Debt
12,413
13,536
14,774
17,641
15,388
14,590
14,080
11,668
10,909
2,699
5,825
9,155
10,775
10,864
14,272
26,535
31,198
Total Equity
28.96
25.11
17.85
19.52
10.88
12.97
12.59
-0.6
20.9
25.67
29.05
28.27
28.34
25.98
33.89
40.74
41.09
Return on Invested Capital (%)
28.85
21.29
18.79
21.27
10.43
10.21
11.15
-0.77
13.3
39.09
28.19
22.73
24.43
17.8
26.74
35.76
40.11
Return on Capital (%)
44.94
30.67
25.22
27.16
13.71
14.22
16.37
-1.3
24.27
94.66
88.81
62.08
61.86
48.65
84.57
105.31
110.39
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1,633
1,635
4,000
LT Borrowings
40,874
40,868
39,370
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
896
895
894
Market Capitalization
684,603
963,523
823,663

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
62,071
55,629
54,835
Cash, Cash Equivalents & STI
9,914
7,268
5,282
Accounts Receivable, Net
16,107
17,760
18,429
Inventories
12,180
13,744
14,529
Total Current Liabilities
40,141
35,228
36,634
Payables & Accruals
31,327
22,761
22,576
ST Debt
1,633
1,635
4,000
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.64%
38.59%
85.92%
Free Cash Flow
127.74%
212.97%
1,340.58%
Net Income, GAAP
-146.26%
36.58%
94.9%
Sales/Revenue/Turnover
13.43%
22.49%
44.7%
Total Cash Common Dividend
9.88%
14.91%
15.04%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,768
11,303
11,439
13,533
45,043
2025
12,729
15,558
17,601
19,292
65,179
2026
19,799
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.49
3.3
1.08
4.91
11.8
2025
3.07
6.3
6.23
7.42
23.07
2026
8.28
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.3
1.3
1.3
1.3
5.21
2025
1.5
1.5
1.5
1.5
6.02
2026
1.73
- -
- -
- -
- -
Similar Companies
TCM Biotech International Corp. (4169.TWO)
Mayne Pharma Group Limited (MYX.AX)
Oscotec Inc. (039200.KQ)
Gland Pharma Limited (GLAND.BO)
Vectura Group plc (VEC.L)
Roche Holding AG (RHHBF)
Business

Company News

APIChat

  • 247wallst.com

    Move Over AI: Jeff Bezos and NVIDIA Are Quietly Backing a New Breakthrough Industry

  • 247wallst.com

    Where Will Eli Lilly Stock be In 2028?

  • fool.com

    1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't

  • wsj.com

    Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal

  • reuters.com

    Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugs

  • fool.com

    Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out

  • prnewswire.com

    Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

  • seekingalpha.com

    Top 25 High-Growth Dividend Stocks For June 2026

  • fool.com

    These 8 Words From Eli Lilly's CEO Have Wall Street Turning Bullish

  • 247wallst.com

    Eli Lilly Growing at 55% as a Trillion-Dollar Company: ‘These Are NVIDIA-Like Growth Numbers'

  • reuters.com

    Unit of China's Haisco, Eli Lilly sign collaboration, licensing deals

  • gurufocus.com

    Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

  • prnewswire.com

    Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

  • seekingalpha.com

    Invesco Summit Fund Q1 2026 Portfolio Update

  • fool.com

    Stock Split Watch: Is Eli Lilly Next?

  • zacks.com

    LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?

  • gurufocus.com

    Lilly Reopens Zepbound Access For 10 Million US Patients

  • seekingalpha.com

    Eli Lilly and Company (LLY) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

  • seekingalpha.com

    Eli Lilly Expands Into Infectious Diseases, Retatrutide Adds Another Phase 3 Win

  • fool.com

    VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost